NCT05806567View on ClinicalTrials.gov

A Study to Assess the Effect of Oral Belumosudil on Inhibition of Various Proteins in the Fed State in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

July 27, 2022

Primary Completion Date

October 20, 2022

Study Completion Date

October 28, 2022

Conditions
Immune System DisorderHealthy Volunteers
Interventions
DRUG

Belumosudil

Pharmaceutical form: Tablet; Route of administration: Oral

DRUG

UGT1A1 victim drug

Pharmaceutical form: Tablet; Route of administration: Oral

DRUG

P-gp victim drug

Pharmaceutical form: Capsule; Route of administration: Oral

DRUG

OATP1B1/BCRP victim drug

Pharmaceutical form: Tablet; Route of administration: Oral

Trial Locations (1)

33126

Investigational Site Number: 8400001, Miami

All Listed Sponsors
lead

Kadmon, a Sanofi Company

INDUSTRY